These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17394071)

  • 1. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients.
    Li Y; Nie Y; Xie J; Tang W; Liang P; Sha W; Yang H; Zhou Y
    Dig Dis Sci; 2007 Nov; 52(11):2942-9. PubMed ID: 17394071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serotonin transporter gene polymorphisms in irritable bowel syndrome and their impact on tegaserod treatment].
    Li YY; Nie YQ; Xie J; Tan HZ; Zhou YJ; Wang H
    Zhonghua Nei Ke Za Zhi; 2006 Jul; 45(7):552-5. PubMed ID: 17074108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin transporter gene polymorphisms in Southwestern Iranian patients with irritable bowel syndrome.
    Farjadian S; Fakhraei B; Moeini M; Nasiri M; Fattahi MR
    Arab J Gastroenterol; 2013 Jun; 14(2):59-62. PubMed ID: 23820502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
    Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
    Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of tegaserod in the treatment of irritable bowel syndrome.
    Patel S; Berrada D; Lembo A
    Expert Opin Pharmacother; 2004 Nov; 5(11):2369-79. PubMed ID: 15500384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients.
    Wang YM; Chang Y; Chang YY; Cheng J; Li J; Wang T; Zhang QY; Liang DC; Sun B; Wang BM
    Neurogastroenterol Motil; 2012 Jun; 24(6):560-5, e254-5. PubMed ID: 22435794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation.
    Novick J; Miner P; Krause R; Glebas K; Bliesath H; Ligozio G; Rüegg P; Lefkowitz M
    Aliment Pharmacol Ther; 2002 Nov; 16(11):1877-88. PubMed ID: 12390096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
    Reilly MC; Barghout V; McBurney CR; Niecko TE
    Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
    Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tegaserod maleate in the treatment of irritable bowel syndrome: a clinical review.
    Rivkin A
    Clin Ther; 2003 Jul; 25(7):1952-74. PubMed ID: 12946544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.
    Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H
    Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome.
    Van Kerkhoven LA; Laheij RJ; Jansen JB
    Aliment Pharmacol Ther; 2007 Oct; 26(7):979-86. PubMed ID: 17877505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
    Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
    Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population.
    Sikander A; Rana SV; Sinha SK; Prasad KK; Arora SK; Sharma SK; Singh K
    J Clin Gastroenterol; 2009; 43(10):957-61. PubMed ID: 19687750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In brief: Tegaserod (Zelnorm) returns.
    Med Lett Drugs Ther; 2019 May; 61(1571):72. PubMed ID: 31169806
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.
    Fock KM; Wagner A;
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1190-8. PubMed ID: 17524039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serotonin transporter gene polymorphism in healthy adults and patients with irritable bowel syndrome].
    Lee DY; Park H; Kim WH; Lee SI; Seo YJ; Choi YC
    Korean J Gastroenterol; 2004 Jan; 43(1):18-22. PubMed ID: 14745247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod for the Treatment of Irritable Bowel Syndrome.
    Madia VN; Messore A; Saccoliti F; Tudino V; De Leo A; De Vita D; Bortolami M; Scipione L; Pindinello I; Costi R; Di Santo R
    Antiinflamm Antiallergy Agents Med Chem; 2020; 19(4):342-369. PubMed ID: 31518227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.